Healthcare Epidemiology - UNC Center for Public Health
... http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf Hand hygiene Guidelines: http://www.cdc.gov/mmwr/PDF/rr/rr5116.pdf Interim Recommendations for Infection Control in Health-Care Facilities Caring for Patients with Known or Suspected Avian Influenza. http://www.cdc.gov/flu/avian/profess ...
... http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf Hand hygiene Guidelines: http://www.cdc.gov/mmwr/PDF/rr/rr5116.pdf Interim Recommendations for Infection Control in Health-Care Facilities Caring for Patients with Known or Suspected Avian Influenza. http://www.cdc.gov/flu/avian/profess ...
Viral respiratory disease in pregnancy
... illness, within the first 48 h of symptoms, they have been shown to decrease the time to recovery by 1 day [4]. The two neuraminidase inhibitors used in the treatment of influenza are zanamivir and oseltamivir. They act to decrease the activity of neuraminidase, which prevents the influenza virus fr ...
... illness, within the first 48 h of symptoms, they have been shown to decrease the time to recovery by 1 day [4]. The two neuraminidase inhibitors used in the treatment of influenza are zanamivir and oseltamivir. They act to decrease the activity of neuraminidase, which prevents the influenza virus fr ...
View/Open - Minerva Access
... H1N1 influenza viruses resistant to oseltamivir, the most widely available neuraminidase inhibitor (NAI), arose in Northern Europe during the 2007/8 influenza season (Lackenby et al., 2008) and spread rapidly around the globe (Hurt et al., 2009) before being replaced by the A(H1N1)pdm09 strain that ...
... H1N1 influenza viruses resistant to oseltamivir, the most widely available neuraminidase inhibitor (NAI), arose in Northern Europe during the 2007/8 influenza season (Lackenby et al., 2008) and spread rapidly around the globe (Hurt et al., 2009) before being replaced by the A(H1N1)pdm09 strain that ...
Recommended composition of influenza virus vaccines for use in
... contained an H431Y amino acid substitution in the neuraminidase; these substitutions were associated with reduced inhibition and highly reduced inhibition, respectively, by all four neuraminidase inhibitors – oseltamivir, zanamivir, peramivir and laninamivir. The neuraminidase inhibitor treatment hi ...
... contained an H431Y amino acid substitution in the neuraminidase; these substitutions were associated with reduced inhibition and highly reduced inhibition, respectively, by all four neuraminidase inhibitors – oseltamivir, zanamivir, peramivir and laninamivir. The neuraminidase inhibitor treatment hi ...
Outbreaks of influenza A in nursing homes in
... home A, one-third of the permanent staff were off sick for the duration of the outbreak. The team approach we employed together with rapid laboratory diagnosis provided an opportunity to employ chemoprophylaxis. The outbreak control team considered the use of amantadine as chemoprophylaxis but this ...
... home A, one-third of the permanent staff were off sick for the duration of the outbreak. The team approach we employed together with rapid laboratory diagnosis provided an opportunity to employ chemoprophylaxis. The outbreak control team considered the use of amantadine as chemoprophylaxis but this ...
Pandemic Influenza
... Estimates based on past pandemics suggest demand for inpatient beds and assisted ventilation may increase by 25%** *Based on CDC’s FluAid pandemic modeling software ** CDC. National Pandemic Influenza Preparedness Plan ...
... Estimates based on past pandemics suggest demand for inpatient beds and assisted ventilation may increase by 25%** *Based on CDC’s FluAid pandemic modeling software ** CDC. National Pandemic Influenza Preparedness Plan ...
C4D & Child Survival in West and Central Africa
... 2. Prevent human H5N1 infections. Pandemic preparedness is largely unrelated to AI response ...
... 2. Prevent human H5N1 infections. Pandemic preparedness is largely unrelated to AI response ...
Budnick slides
... • For non-specific outcomes pooled data from three C-RCTs showed HCW vaccination reduced ILI; data from one C-RCT that HCW vaccination reduced GP consultations for ILI; and pooled data from three C-RCTs showed reduced all-cause mortality in individuals >/= 60. • Non-specific outcomes are difficult t ...
... • For non-specific outcomes pooled data from three C-RCTs showed HCW vaccination reduced ILI; data from one C-RCT that HCW vaccination reduced GP consultations for ILI; and pooled data from three C-RCTs showed reduced all-cause mortality in individuals >/= 60. • Non-specific outcomes are difficult t ...
Influenza Infection in Humans
... • Describe the characteristics of influenza infection in humans • Understand different types of influenza viruses and how they can infect humans and animals • Describe the ways that influenza viruses can change or mutate ...
... • Describe the characteristics of influenza infection in humans • Understand different types of influenza viruses and how they can infect humans and animals • Describe the ways that influenza viruses can change or mutate ...
APP9NwanzeC - Environmental Public Health Today
... To educate and equip pregnant women on the effects of the pandemic flu and how they can prevent and/or take care of themselves during the flu season. ...
... To educate and equip pregnant women on the effects of the pandemic flu and how they can prevent and/or take care of themselves during the flu season. ...
Antivirals
... Prophylaxis In some countries, Relenza® may also be used as prophylaxis to prevent infection either before or after exposure to influenza. The usual preventative dose is an inhalation of two “blisters” (10mg).once a day, for 10 days following exposure or for the duration of exposure. ...
... Prophylaxis In some countries, Relenza® may also be used as prophylaxis to prevent infection either before or after exposure to influenza. The usual preventative dose is an inhalation of two “blisters” (10mg).once a day, for 10 days following exposure or for the duration of exposure. ...
Relenza inhalation powder pre
... Relenza is not a substitute for influenza vaccination and the use of Relenza must not affect the evaluation of individuals for annual vaccination. The protection against influenza only lasts as long as Relenza is administered. Relenza should be used for the treatment and prevention of influenza only ...
... Relenza is not a substitute for influenza vaccination and the use of Relenza must not affect the evaluation of individuals for annual vaccination. The protection against influenza only lasts as long as Relenza is administered. Relenza should be used for the treatment and prevention of influenza only ...
What is Avian Influenza?
... – Threat to food security – Widespread public anxiety – Global and national attention on government’s response ...
... – Threat to food security – Widespread public anxiety – Global and national attention on government’s response ...
EMERGING INFECTIOUS DISEASES: Vol. 16, No. 4 • April 2010
... Rapid, large-scale risk-based entry screening of air travelers for ILI that used questionnaires and health assessments was conducted successfully at 2 airports for 177 flights. Seventy-five percent of passengers who provided contact details were followed up, but few of those with symptoms were prep ...
... Rapid, large-scale risk-based entry screening of air travelers for ILI that used questionnaires and health assessments was conducted successfully at 2 airports for 177 flights. Seventy-five percent of passengers who provided contact details were followed up, but few of those with symptoms were prep ...
Pandemic Planning Manual - Hawkes Bay District Health Board
... Very rarely, an avian influenza virus can also infect people. The current avian influenza virus – H5N1 – has infected some people who have caught it from having close contact with infected birds. Avian influenza causes severe flu-like symptoms in people and may result in death. It has not been shown ...
... Very rarely, an avian influenza virus can also infect people. The current avian influenza virus – H5N1 – has infected some people who have caught it from having close contact with infected birds. Avian influenza causes severe flu-like symptoms in people and may result in death. It has not been shown ...
Efforts to Increase Influenza Testing in New Mexico
... complete medical charts when compared to those seen at the ED; however, medical information was not consistently found in the electronic medical chart for patients whether admitted or not. It is possible that paper medical records are more complete at this hospital; however, paper records were not r ...
... complete medical charts when compared to those seen at the ED; however, medical information was not consistently found in the electronic medical chart for patients whether admitted or not. It is possible that paper medical records are more complete at this hospital; however, paper records were not r ...
Genetic Strategy to Prevent Influenza Virus Infections in Animals
... the avian influenza A(H5N1) virus demands the rapid development of new vaccines and the stockpiling of existing antiviral drugs. However, the limited efficacy and scope of current vaccines and antiviral drugs also demands the development of fundamentally new strategies to control influenza epidemics ...
... the avian influenza A(H5N1) virus demands the rapid development of new vaccines and the stockpiling of existing antiviral drugs. However, the limited efficacy and scope of current vaccines and antiviral drugs also demands the development of fundamentally new strategies to control influenza epidemics ...
Influenza Immunization for Health Care Workers Dr. Lisa Simon
... Programs: A Guide for Program Planners“: 5 Steps to Planning an Effective Immunization Program, from establishing program team through to evaluation Includes 5 effective strategies previously discussed Includes guidance for calculating immunization rates Associated tools, and Ottawa Influenz ...
... Programs: A Guide for Program Planners“: 5 Steps to Planning an Effective Immunization Program, from establishing program team through to evaluation Includes 5 effective strategies previously discussed Includes guidance for calculating immunization rates Associated tools, and Ottawa Influenz ...
pdf version here - Health Sciences Authority
... beneficial effects in the management of the disease condition, however, they may also cause side effects in certain patients. Given the current H1N1 pandemic with its associated increase in the use of antivirals, including oseltamivir (Tamiflu®) and zanamivir (Relenza®) to treat patients at risk of ...
... beneficial effects in the management of the disease condition, however, they may also cause side effects in certain patients. Given the current H1N1 pandemic with its associated increase in the use of antivirals, including oseltamivir (Tamiflu®) and zanamivir (Relenza®) to treat patients at risk of ...
TAMIFLU Product Monograph
... with first dosing. These events did not lead to patient discontinuation of study drug in the vast majority of instances. At the recommended dose of 75 mg twice daily, the most frequently reported adverse events that led to patient withdrawal were nausea and vomiting. In adult/adolescent phase III tr ...
... with first dosing. These events did not lead to patient discontinuation of study drug in the vast majority of instances. At the recommended dose of 75 mg twice daily, the most frequently reported adverse events that led to patient withdrawal were nausea and vomiting. In adult/adolescent phase III tr ...
TAMIFLU Product Monograph
... with first dosing. These events did not lead to patient discontinuation of study drug in the vast majority of instances. At the recommended dose of 75 mg twice daily, the most frequently reported adverse events that led to patient withdrawal were nausea and vomiting. In adult/adolescent phase III tr ...
... with first dosing. These events did not lead to patient discontinuation of study drug in the vast majority of instances. At the recommended dose of 75 mg twice daily, the most frequently reported adverse events that led to patient withdrawal were nausea and vomiting. In adult/adolescent phase III tr ...
Influenza: Virus and Disease, Epidemics and Pandemics (Steinhoff)
... Copyright 2007, The Johns Hopkins University and Mark Steinhoff. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided “AS IS”; no representations or warranties provided. User assumes all responsibility for use, and all liability rel ...
... Copyright 2007, The Johns Hopkins University and Mark Steinhoff. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided “AS IS”; no representations or warranties provided. User assumes all responsibility for use, and all liability rel ...
Influenza Prevention and Control
... summer or early fall—as soon as the vaccine is available. However, there is still a potential benefit if a child gets a flu vaccine as late as April or May or even through June of the following year. Influenza viruses can occasionally circulate into April and May or even later. A child will still ne ...
... summer or early fall—as soon as the vaccine is available. However, there is still a potential benefit if a child gets a flu vaccine as late as April or May or even through June of the following year. Influenza viruses can occasionally circulate into April and May or even later. A child will still ne ...
Influenza Vaccination Should Be a Condition of Employment
... Influenza is a serious disease that is associated with high rates of morbidity and mortality. In the United States, an estimated 5% to 15% of the population is affected by the virus each year.1 Influenza infections result in approximately 150,000 hospital admissions and 24,000 deaths annually.2 A re ...
... Influenza is a serious disease that is associated with high rates of morbidity and mortality. In the United States, an estimated 5% to 15% of the population is affected by the virus each year.1 Influenza infections result in approximately 150,000 hospital admissions and 24,000 deaths annually.2 A re ...
Oseltamivir
Oseltamivir INN /ɒsəlˈtæmɨvɪər/, marketed under the trade name Tamiflu, is an antiviral medication used to treat influenza A and influenza B (flu), and to prevent flu after exposure. The medication is taken orally.The Infectious Disease Society of America, the United States' Centers for Disease Control and Prevention (CDC), and the United Kingdom's National Institute for Health and Care Excellence recommend the use of oseltamavir for people who have complications or are at high risk for complications who present within 48 hours of first symptoms of infection. They recommend its use to prevent infection in at-risk people but not the general population. The CDC recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection. However, these recommendations are controversial as are criticisms of the recommendations. A Cochrane review concluded that oseltamivir does not reduce hospitalizations, and that there is no evidence of reduction in complications of influenza (such as pneumonia) because of a lack of diagnostic definitions, or reduction of the spread of the virus. Two meta-analyses have concluded that benefits in those who are otherwise healthy do not outweigh its risks. They also found little evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations. However, another meta-analysis found that oseltamivir was effective for prevention of influenza at the individual and household levels.Side effects include psychiatric symptoms, increased rates of vomiting, and headaches. It is pregnancy category C in the United States and category B in Australia meaning that it has been taken by a small number of women without signs of problems and in animal studies it looks safe. Dose adjustment may be needed in those with kidney problems.It was the first orally administered neuraminidase inhibitor commercially developed. It was discovered and developed by US-based Gilead Sciences, which licensed the exclusive rights to Roche in 1996. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.